
Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
Published on December 6, 2021
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.
